Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | Special approaches to myeloma patients with high-risk cytogenetics

Pieter Sonneveld • 13 May 2022
COMy 2022
Multiple Myeloma

Pieter Sonneveld, MD, PhD, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands, highlights the key points from his presentation at COMy 2022 on how to approach patients with high-risk cytogenetics in multiple myeloma. Prof. Sonneveld notes some of the challenges including the multiple definitions used to define high-risk disease, as well as lower numbers of patients included in clinical trials. In this video, Prof. Sonneveld describes the suggestions he made at the COMy 2022 meeting to address these issues. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

More from Pieter Sonneveld

2:54
The PERSEUS trial: primary results of D-VRd vs VRd in newly diagnosed, transplant eligible MM
Pieter Sonneveld • 11 Dec 2023
Reaching a cure for multiple myeloma
Gareth Morgan et al. • 15 Apr 2023
1:57
The benefit of double autologous transplantation in multiple myeloma patient subgroups
Pieter Sonneveld • 24 Oct 2022
1:27
Do CAR-T therapies play a role in earlier lines of therapy in multiple myeloma?
Pieter Sonneveld • 24 Oct 2022

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals